Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.

Heart failure and obstructive sleep apnea frequently coexist and are linked through complex pathophysiological mechanisms, including intermittent hypoxemia, sympathetic activation, oxidative stress, and hemodynamic alterations. This bidirectional interaction contributes to disease progression, impaired quality of life, and adverse clinical outcomes. While CPAP remains the standard treatment for OSA, treatment response in patients with coexisting HF is variable, and additional therapeutic strategies targeting both conditions are of clinical interest.

Sodium-glucose cotransporter-2 inhibitors, including empagliflozin, have demonstrated significant cardiovascular benefits in patients with HF. Their mechanisms of action, including osmotic diuresis, reduction in intravascular and interstitial fluid volume, and improvement in cardiac function, may also influence the pathophysiology of OSA, particularly by reducing nocturnal rostral fluid shift and upper airway collapsibility. However, prospective randomized data evaluating the effects of SGLT2i on sleep-disordered breathing in patients with HF and OSA remain limited.

This randomized controlled clinical trial was designed to evaluate the effects of empagliflozin on sleep, cardiac, and biochemical outcomes in adults with coexisting HF and OSA, and to assess the impact of subsequent CPAP therapy. The study incorporated a sequential two-phase design to allow differentiation between the early effects of pharmacological therapy and the later effects of CPAP.

In the first phase (0-3 months), participants were randomly assigned in a 1:1 ratio to receive empagliflozin in addition to background HF therapy or to continue background HF therapy without empagliflozin. This phase was designed to evaluate the isolated effect of empagliflozin on OSA severity, nocturnal oxygenation, cardiac function, and oxidative stress.

In the second phase (3-6 months), CPAP therapy was initiated in all participants, while empagliflozin treatment was continued in the study group. This phase was designed to assess the effect of CPAP therapy in both groups and to explore whether prior exposure to empagliflozin influenced the response to CPAP.

Assessments were performed at baseline, 3 months, and 6 months. Sleep-related outcomes included apnea-hypopnea index (AHI), mean oxygen saturation (MOS), lowest oxygen saturation (LOS), and time spent with oxygen saturation below 90% (T<90%), obtained from type III sleep studies. Cardiac outcomes included left ventricular ejection fraction assessed by transthoracic echocardiography and N-terminal pro-B-type natriuretic peptide concentrations. Biochemical analyses included evaluation of oxidative stress markers, including TOS, TAS, and OSI. Patient-reported outcomes included validated questionnaires assessing sleep quality, daytime sleepiness, and quality of life.

The study also included exploratory analyses to assess relationships between sleep-related and cardiac parameters, as well as to evaluate whether baseline OSA severity influenced response to treatment. The sequential design of the study allowed assessment of phase-specific effects and potential interaction between pharmacological therapy and CPAP.

Overall, the study aimed to provide a comprehensive evaluation of the role of empagliflozin as an adjunctive therapy in patients with HF and OSA, and to clarify its potential impact on sleep-disordered breathing, cardiac function, and oxidative stress in the context of subsequent CPAP treatment.

Inclusion criteria

• Age ≥18 years
• Diagnosed heart failure (HF) on stable guideline-directed medical therapy
• Obstructive sleep apnea (OSA) confirmed by sleep study (mild, moderate, or severe)
• No prior treatment with empagliflozin or other sodium-glucose cotransporter-2 inhibitors
• No prior treatment with continuous positive airway pressure therapy
• Body mass index (BMI) <40 kg/m²
• Clinical eligibility for CPAP therapy according to current recommendations
• Ability to provide written informed consent

Exclusion criteria

• Age <18 years
• Body mass index (BMI) ≥40 kg/m²
• Active malignancy
• Severe renal impairment (estimated glomerular filtration rate <25 mL/min/1.73 m²)
• Advanced hepatic insufficiency
• Symptomatic hypotension
• Clinically significant volume depletion or dehydration
• Known hypersensitivity to empagliflozin or any component of the study medication
• Any condition that, in the opinion of the investigator, could interfere with study participation or interpretation of results